210 related articles for article (PubMed ID: 30716523)
1. Voxel-Based Analysis for Identification of Urethrovesical Subregions Predicting Urinary Toxicity After Prostate Cancer Radiation Therapy.
Mylona E; Acosta O; Lizee T; Lafond C; Crehange G; Magné N; Chiavassa S; Supiot S; Ospina Arango JD; Campillo-Gimenez B; Castelli J; de Crevoisier R
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):343-354. PubMed ID: 30716523
[TBL] [Abstract][Full Text] [Related]
2. Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population.
Mylona E; Ebert M; Kennedy A; Joseph D; Denham J; Steigler A; Supiot S; Acosta O; de Crevoisier R
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1189-1195. PubMed ID: 32673785
[TBL] [Abstract][Full Text] [Related]
3. Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects.
Mylona E; Cicchetti A; Rancati T; Palorini F; Fiorino C; Supiot S; Magne N; Crehange G; Valdagni R; Acosta O; de Crevoisier R
Radiother Oncol; 2020 Jun; 147():40-49. PubMed ID: 32224316
[TBL] [Abstract][Full Text] [Related]
4. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
5. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
[TBL] [Abstract][Full Text] [Related]
6. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
[TBL] [Abstract][Full Text] [Related]
7. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
[TBL] [Abstract][Full Text] [Related]
8. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
9. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer.
Ghadjar P; Zelefsky MJ; Spratt DE; Munck af Rosenschöld P; Oh JH; Hunt M; Kollmeier M; Happersett L; Yorke E; Deasy JO; Jackson A
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):339-44. PubMed ID: 24411606
[TBL] [Abstract][Full Text] [Related]
10. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
[TBL] [Abstract][Full Text] [Related]
11. Current status of intensity-modulated radiation therapy for prostate cancer: History, clinical results and future directions.
Hatano K; Tohyama N; Kodama T; Okabe N; Sakai M; Konoeda K
Int J Urol; 2019 Aug; 26(8):775-784. PubMed ID: 31115116
[TBL] [Abstract][Full Text] [Related]
12. Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface.
Yahya N; Ebert MA; House MJ; Kennedy A; Matthews J; Joseph DJ; Denham JW
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):420-426. PubMed ID: 28068247
[TBL] [Abstract][Full Text] [Related]
13. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
[TBL] [Abstract][Full Text] [Related]
16. Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters.
Manea E; Escande A; Bockel S; Khettab M; Dumas I; Lazarescu I; Fumagalli I; Morice P; Deutsch E; Haie-Meder C; Chargari C
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):411-420. PubMed ID: 29559282
[TBL] [Abstract][Full Text] [Related]
17. Associations between volume changes and spatial dose metrics for the urinary bladder during local versus pelvic irradiation for prostate cancer.
Casares-Magaz O; Moiseenko V; Hopper A; Pettersson NJ; Thor M; Knopp R; Deasy JO; Muren LP; Einck J
Acta Oncol; 2017 Jun; 56(6):884-890. PubMed ID: 28401808
[TBL] [Abstract][Full Text] [Related]
18. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
[TBL] [Abstract][Full Text] [Related]
19. An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
Henderson DR; Murray JR; Gulliford SL; Tree AC; Harrington KJ; Van As NJ
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):539-547. PubMed ID: 29807801
[TBL] [Abstract][Full Text] [Related]
20. Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy.
Mavroidis P; Pearlstein KA; Dooley J; Sun J; Saripalli S; Das SK; Wang AZ; Chen RC
Radiat Oncol; 2018 Feb; 13(1):17. PubMed ID: 29394931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
